Tag Archives: clinical trials

PAPR Inhibitors May Work Against More Ovarian Cancers

PAPR inhibitors, first used in trials for women with ovarian cancer who had a mutation in the BRCA1 or BRCA2 gene, are now being used in trials for women without … Continue reading 

Posted in News | Also tagged , , , , , | Leave a comment

Drug Combination to Treat Cancer Expected to Rise

According to an article in the Wall Street Journal, combinations of drugs to treat cancer will be used more frequently in the future. Many studies presented at the 2011 annual … Continue reading 

Posted in News | Also tagged , , , | Leave a comment

Carbo/Doxil in elderly patients

BACKGROUND: CALYPSO (CAeLYx in Platinum Sensitive Ovarian) patients compared carboplatin-pegylated liposomal doxorubicin (C-PLD) with carboplatin-paclitaxel (C-P) in patients with late-relapsing recurrent ovarian cancer (ROC). We analyzed outcomes in patients <70 … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Phase II Trial of Phenoxodial Complete

INTRODUCTION: Chemoresistance is a major limitation in the treatment of ovarian cancer. Phenoxodiol is a novel biomodulator capable of reversing chemoresistance in vitro and in vivo. In this study, we … Continue reading 

Posted in News | Also tagged , , | Leave a comment

ESAs Linked to Ovarian Cancer Mortality (Medpage)

A study presented at the Society for Gynecologic Oncology annual meeting in March, 2011 showed that women treated with ESAs had higher rates of ovarian cancer recurrence and death. ESAs … Continue reading 

Posted in News | Also tagged , , , | Leave a comment

Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations

A new study shows that ovarian cancer patients who had the non-Askenazi Jewish BRCA mutation had longer Progression Free Surivival time and Overall Survival times than ovairan cancer patients who … Continue reading 

Posted in News | Also tagged , | Leave a comment

Results of a Third Phase III Trial of Avastin in Ovarian Cancer Released

Genentech, a member of the Roche group, announced that a third Phase III trial of Avastin in ovarian cancer met its endpoint of improvement in progression free survivial.  See the … Continue reading 

Posted in News | Also tagged , | Leave a comment

New clinical trial to determine ovarian cancer risks in African-American women

University Hospitals Case Medical Center and Case Western Reserve University School of Medicine are conducting an important new study addressing the lack of knowledge about causes and risk factors for … Continue reading 

Posted in News | Leave a comment

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer

Background: A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian … Continue reading 

Posted in News | Also tagged , | Leave a comment

A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer

Retrospective studies and a Phase II trial demonstrated the promising efficacy and safety of intraperitoneal administration of carboplatin in ovarian, fallopian tube and primary peritoneal cancer. A Japanese Gynecologic Oncology … Continue reading 

Posted in News | Also tagged , , | Leave a comment

Unrealistic Optimism in Early-Phase Oncology Trials

A new report questions the ethics of early stage oncology clinical trials, asserting that since patients have unrealistically high expectations of the outcomes of the trials, a question of informed … Continue reading 

Posted in News | Also tagged | Leave a comment

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

Purpose Weekly administration of topotecan (Tw) is less toxic and widely considered a better treatment option than conventional 5-day therapy (Tc) in women with platinum-resistant recurrent ovarian cancer. We conducted … Continue reading 

Posted in News | Also tagged , , , | Leave a comment